Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy
Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy
This is a multi-center, long-term safety and efficacy follow-up study for subjects with
 hemoglobinopathies (β-thalassemia or severe sickle cell disease) who have been treated with
 ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After
 completing the parent clinical study (approximately 2 years), eligible subjects will be
 followed for an additional 13 years for a total of 15 years post-drug product infusion. No
 investigational drug product will be administered in the study.
Inclusion Criteria:

 -  Provision of written informed consent for this study by subjects, or as applicable,
 subject's parent(s)/legal guardian(s)

 -  Treated with drug product for therapy of a hemoglobinopathy in a bluebird
 bio-sponsored clinical study

 -  Able to comply with study requirements

 Exclusion Criteria:

 -  There are no exclusion criteria for this study